The study found that there has been a significant increasing trend in patients with migraine—irrespective of aura status—having an ischemic stroke.
The director of the Center of Neurogenetics at Weill Cornell Medicine spoke about the wealth of improvements that have really turned this area of medicine into a much more hopeful one.
The founder and CEO of T3D Therapeutics, Inc., spoke about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.
The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.
The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.
Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
The associate chief of the MS division and professor of neurology at Penn Medicine described the ongoing relationship between artificial intelligence and neurologists, and how it may evolve in the future.
The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about the difference in conversation for therapies between pediatric patients and adult patients with MS. [WATCH TIME: 5 minutes]
The full approval for BNT162b2 (Comirnaty; Pfizer/BioNTech) will afford physicians greater prescribing capability and is expected to play a role in driving workplace vaccine mandates.
Neurological rehabilitation, or neurorehabilitation, can be described as the use of rehabilitation interventions to improve or maintain function and quality of life in the context of neurological conditions.
The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDlesstrial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]
Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.
The research fellow at the University of Exeter spoke about the findings from her observational study which showed that living a favorable lifestyle could offset the risk for dementia, even if that risk is genetically linked. 


Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.
The director of Behavioral Medicine at the Mellen Center for MS Treatment and Research at the Cleveland Clinic spoke about the importance of caring for patients with MS by using a team-based approach.
At the 2022 AES Conference, the Baldwin Keyes professor of neurology at Thomas Jefferson University, talked about what defines a ‘seizure’ and changing the terminology. [WATCH TIME: 5 minutes]
The director of Pediatric Epilepsy at Centennial Children's Hospital spoke about the need to increase epilepsy's awareness and the clinical development of several agents that he is keeping his eyes on.
The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.
The professor of epilepsy and medical education at St. George’s University Hospital London spoke about the number of challenges plaguing epileptologists when treating patients who present with possible status epilepticus in the hospital.
Despite being labeled as rare diseases, a number of neurologic conditions impact more patients than most would believe. The consultant with expertise in ophthalmology, gene therapy, and rare and orphan diseases, chimed in about how these diseases can often be overlooked.
The director of epilepsy surgery and associate professor of neurosurgery at UC Irvine spoke to the advances that have been made in epilepsy surgery and in noninvasive or minimally invasive techniques, as well as the impact they’ve had on outcomes.
The child neurology resident at NYU Langone spoke about ways for residents to identify and address impaired colleagues that suffer from depression and burnout.
Haeberlein spoke about a number of topics in the Alzheimer space, including the progress that has been made and her excitement for the future.
The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine spoke about preserving brain function through medical, sociopolitical, and educational efforts as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]